Cell Medica Ltd has appointed Chris Nowers as its new chief executive to succeed the founder and CEO Gregg Sando who has stepped down to pursue new ventures. Mr Nowers joins the company from Kite Pharma, part of Gilead Sciences Inc, where he was responsible for the commercialisation of Yescarta, a chimeric antigen receptor (CAR) T cell therapy for lymphoma.
Prior to this, he was CEO of Avantogen Oncology Inc and a senior manager at both Amgen Inc and Bristol-Myers Squibb Co.
Cell Medica has a portfolio of cancer immunotherapies that include CAR T cell products as well as engineered T cell receptors. The CAR therapies use natural killer T cells, which are a subset of T cells.
Cell Medica announced the appointment on 1 August 2018.
Copyright 2018 Evernow Publishing Ltd.